Checkpoint Inhibitor denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for checkpoint inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits Checkpoint Inhibitor Quantities — and Why You Can Appeal

Checkpoint inhibitors (PD-1, PD-L1, and CTLA-4 inhibitors) are administered on dosing schedules set by each drug's FDA-approved prescribing label. UnitedHealthcare applies quantity or frequency limits that are calibrated to what it considers the standard labeled regimen. A denial is triggered when the submitted claim exceeds those limits — whether because your oncologist is using a weight-based or flat-dose variation, an extended interval schedule, or a combination regimen.

This type of denial is consistently appealable because the FDA-approved labeling itself describes multiple dosing options and schedules, and published oncology guidelines from organizations such as NCCN support individualized regimen selection based on tumor type, stage, and prior treatment history.

## Federal Appeal Rights

You have layered federal protections:

• Internal appeal (ERISA §503 / ACA): You must typically file within 180 days of the denial. The plan must respond within 60 days (30 days for pre-service).
• External review (ACA §2719): After exhausting internal appeals, or if the internal appeal is upheld, you may request independent external review. The external reviewer is not bound by the plan's own policies and must evaluate medical necessity against generally accepted clinical standards. Request this within approximately 4 months of the final internal denial.
• Expedited review: If your condition is urgent, you may request an expedited internal and/or external review with a 72-hour turnaround.

## What to Gather

1. Diagnosis confirmation: Pathology report, molecular/biomarker testing (e.g., PD-L1 expression, tumor mutational burden, MSI status) — the exact markers that determine checkpoint inhibitor eligibility per your prescriber's chosen regimen. 2. Regimen justification: A letter from your oncologist explaining why the prescribed schedule and quantity are medically necessary, citing the specific FDA label provisions and applicable NCCN guideline recommendation that support the chosen regimen. 3. Prior treatment history: Dates and outcomes of any prior lines of therapy, showing where in the treatment sequence this agent falls. 4. Clinical severity documentation: Performance status, disease staging, and any comorbidities that influence scheduling decisions. 5. Insurer's published policy: Download UHC's current medical/coverage policy for this agent. Note every stated quantity or frequency criterion.

## Criteria-Mapping Structure

Build a table or numbered list:

| UHC Policy Requirement | Supporting Chart Documentation | |---|---| | Approved indication per FDA label | Pathology + biomarker results confirming indication | | Quantity/frequency within labeled range | Prescriber letter citing label section and schedule | | Regimen consistent with guideline (e.g., NCCN) | Oncologist attestation citing guideline category/recommendation | | Any required prior authorization criteria | Prior auth submission records |

Address each line item with the exact page, date, or result from the chart. The external reviewer will compare your documentation against accepted clinical standards — a well-mapped submission significantly improves outcomes.